Glaxosmithkline Pharmaceuticals Ltd Share Price – NSE  /  BSE

Pharmaceuticals, Small Cap

GlaxoSmithKline Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 17 May 2024.

Powered by Capital Market - Live News

Glaxosmithkline Pharmaceuticals Ltd is down for a fifth straight session today. The stock is quoting at Rs 2049.1, down 0.04% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.43% on the day, quoting at 22397.5. The Sensex is at 73785.71, down 0.45%.Glaxosmithkline Pharmaceuticals Ltd has lost around 12.44% in last one month.Meanwhile, Nifty Pharma index of which Glaxosmithkline Pharmaceuticals Ltd is a constituent, has increased around 3.4% in last one month and is currently quoting at 19194.1, up 0.57% on the day. The volume in the stock stood at 59846 shares today, compared to the daily average of 1.64 lakh shares in last one month.

The PE of the stock is 54.65 based on TTM earnings ending December 23.

Powered by Capital Market - Live News

Glaxosmithkline Pharmaceuticals Ltd is down for a fifth straight session today. The stock is quoting at Rs 2203.15, down 5.85% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.35% on the day, quoting at 21690.7. The Sensex is at 71414.04, up 0.48%.Glaxosmithkline Pharmaceuticals Ltd has lost around 2.48% in last one month.Meanwhile, Nifty Pharma index of which Glaxosmithkline Pharmaceuticals Ltd is a constituent, has increased around 6.94% in last one month and is currently quoting at 18669.55, up 0.36% on the day. The volume in the stock stood at 4.87 lakh shares today, compared to the daily average of 2.09 lakh shares in last one month.

The PE of the stock is 62.76 based on TTM earnings ending September 23.

Powered by Capital Market - Live News

Revenue from operations rose marginally to Rs 805.26 crore in the quarter ended 31 December 2023 from Rs 802.30 crore posted in corresponding quarter last year.

Profit before tax stood at Rs 65.43 crore for the quarter, down by 70.82% as compared to Rs 224.25 crore recorded in Q3 FY23.

The pharma company’s EBITDA margin stood at 27% during the quarter.

On nine-month basis, the company recorded 17.14% YoY decline in consolidated profit to Rs 395.48 crore in 9M FY24. Revenue from operations increased 2.42% to Rs 2,523.91 crore in 9M FY24 from Rs 2,464.27 crore posted in the corresponding period previous year.

The drug maker stated that in flat general medicines represented market during the quarter; GSK recorded 1% value growth despite the NLEM impact. Augmentin improved its market share and retained no. 1 rank in the IPM (Indian Pharmaceutical Market). Vaccines market and portfolio continued to deliver sequential growth.

GSK added that it will continue to invest in building newer capabilities to improve reach and access for its innovative portfolio comprising Shingrix, Nucala and Trelegy.

Bhushan Akshikar, managing director, GlaxoSmithKline Pharmaceuticals said, We remain committed to new category development in areas like Adult Immunization with products like Shingrix to make a positive impact to the lives of the patients in India. We will continue to drive operational efficiency and explore new innovative solutions including Omnichannel Strategy to expand reach and coverage to the target segments.”

GlaxoSmithKline Pharmaceuticals is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies.

Powered by Capital Market - Live News